ArticleNature medicine2025

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Saad Z Usmani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.